Trial Profile

A clinical study of CYMS101 for treatment of Multiple Sclerosis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYMS 101 (Primary)
Indications Multiple sclerosis
Focus Adverse reactions

Most Recent Events

19 Jan 2026 New trial record
07 Jan 2026 According to a FibroBiologics media release, company is advancing CYMS101 toward an IND submission for multiple sclerosis, supported by remyelination data. Ongoing CDMO and CRO engagements are expected to position the program for multiple clinical trials in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com